POSA6 Use of Real-World Evidence to Evaluate Infliximab Biosimilars: A Scoping Review

Abstract

Authors

A Cheung LC Powell T Rahim S Emerson K Johnston

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×